Evidence map›Paper›PMID 28148553›Full record

ArticleEMBO molecular medicine2017

PERK activation mitigates tau pathology

Julius Bruch, Hong Xu, Thomas W Rösler, Anderson De Andrade, Peer-Hendrik Kuhn, Stefan F Lichtenthaler, Thomas Arzberger, Konstanze F Winklhofer, Ulrich Müller, Günter U Höglinger

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 122 citations in OpenAlex.

  1. Progressive Supranuclear Palsy PERK Haplotype B Selectively Translates DLX1 Promoting Tau Toxicity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Julius BruchDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Hong XuDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Thomas W RöslerDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Anderson De AndradeDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Peer-Hendrik KuhnNeuroproteomics, Klinikum rechts der Isar and Institute for Advanced Study, Technical University of Munich (TUM), Munich, Germany.
Stefan F LichtenthalerMunich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Thomas ArzbergerCenter for Neuropathology and Prion Research (ZNP), University of Munich, Munich, Germany.
Konstanze F WinklhoferMunich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Ulrich MüllerInstitute for Human Genetics, University of Giessen, Giessen, Germany.
Günter U HöglingerDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany guenter.hoeglinger@dzne.de.ORCID 0000-0001-7587-6187
German Center for Neurodegenerative Diseases · DEJustus-Liebig-Universität Gießen · DEMunich Cluster for Systems Neurology · DETUM Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The RNA-like endoplasmic reticulum kinase (PERK) is genetically associated with the tauopathy progressive supranuclear palsy (PSP). To elucidate the functional mechanisms underlying this association, we explored PERK activity in brains of PSP patients and its function in three tauopathy models (cultured human neurons overexpressing 4-repeat wild-type tau or treated with the environmental neurotoxin annonacin, and P301S tau transgenic mice).

Indexed as

AnimalsBrainCells, CulturedCell SurvivaleIF-2 KinaseHumansLocomotionMemoryMice, TransgenicPhosphorylationProtein ConformationProtein Processing, Post-TranslationalTauopathiestau ProteinsEIF2AK3 protein, humaneIF-2 KinaseMAPT protein, humantau ProteinsEIF2ANRF2PERKprogressive supranuclear palsytauopathy

Identifiers

PMID28148553
PMCPMC5331260
OpenAlexW2583987092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.